Increasing the dose of aclarubicin in low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) can safely and effectively treat relapsed or refractory acute myeloid leukemia |
| |
Authors: | Limin Liu Yanming Zhang Zhengming Jin Xingxia Zhang Guangsheng Zhao Yejun Si Guoqiang Lin Aidi Ma Yingxin Sun Li Wang Depei Wu |
| |
Institution: | 1. The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, 188 Shizi Street, Suzhou, 215006, Jiangsu, People’s Republic of China 2. Department of Hematology, The Second People’s Hospital of Huai’an, 62 Huaihai South Street, Huai’an, 223002, People’s Republic of China
|
| |
Abstract: | It is difficult for relapsed and refractory acute myeloid leukemia (AML) patients to achieve complete remission (CR). The CAG regimen low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (G-CSF)] has been used to treat relapsed and refractory AML patients, and showed good therapeutic efficacy. It is unknown, however, whether increasing the dose of aclarubicin in CAG regimen could treat relapsed or refractory AML safely and effectively. We evaluate the efficacy and tolerability of increasing the dose of aclarubicin in CAG regimen, in 37 relapsed or refractory AML patients. All patients were treated with CAG regimen including low-dose cytarabine (10 mg/m2 every 12 h, days 1–14), aclarubicin (5–7 mg/m2 every day, days 1–14), and G-CSF (200 μg/m2 every day, days 1–14) priming. After a single course of therapy, the overall response CR + partial remission (PR)] rate of all patients was 78.4 % (29/37), in which the CR rate was 62.2 % (23/37). There was no early death. The median overall survival was 6 months (range 2–36 months). Myelosuppression was ubiquitous, but tolerated. No severe non-hematologic toxicity was observed. Thus, increasing the dose of aclarubicin in CAG regimen can be used safely and effectively in the treatment of relapsed or refractory AML. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|